Expression and biological significance of LncRNA ILF3-AS1 in prostate cancer tissue

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000030323

Enrollment

Unknown

Registered

2020-02-28

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

case series:N/A

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Pathological examination to confirm prostate cancer patients; 2. Informed consent acquisition of its prostate cancer.

Exclusion criteria

Exclusion criteria: 1. Patients with steroid-resistant at the first time treatment; 2. Narcotic drug allergy.

Design outcomes

Primary

Measure	Time frame
LncRNA ILF3-AS1;	—

Countries

China

Contacts

Public ContactLibo Xie

Affiliated Hospital of Southwest Medical Univeristy

peterxielibo@163.com+86 18208344963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026